Clinical Trial Update: Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial investigating allo-immunity to boost immune checkpoint inhibitor responses in Stage IV non-small cell lung cancer has been with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: VA Office of Research and Development | Conditions: Stage IV NSCLC | Phase 1, Phase 2 | Status: WITHDRAWN